Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients

Breast Cancer Research and Treatment

Volumn 108, Issue 2, 2008, Pages 233-240

  Chang, Jenny C ^a   Makris, Andreas ^b   Gutierrez, M Carolina ^a   Hilsenbeck, Susan G ^a   Hackett, James R ^c   Jeong, Jennie ^c   Liu, Mei Lan ^c   Baker, Joffre ^c   Clark Langone, Kim ^c   Baehner, Frederick L ^c   Sexton, Krsytal ^a   Mohsin, Syed ^a   Gray, Tara ^a   Alvarez, Laura ^a   Chamness, Gary C ^a   Osborne, C Kent ^a   Shak, Steven ^c  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c Genomic Health Inc   (United States)

Author keywords

Docetaxel chemosensitivity; Paraffin embedded material; Predictive markers

Indexed keywords

DOCETAXEL; FORMALDEHYDE; PARAFFIN; RNA;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CHEMOSENSITIVITY; DISEASE COURSE; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SCORING SYSTEM; TISSUE SECTION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; BIOPSY; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FIXATIVES; FORMALDEHYDE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC SCREENING; GREAT BRITAIN; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOADJUVANT THERAPY; PARAFFIN EMBEDDING; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAXOIDS; TISSUE FIXATION; TREATMENT OUTCOME; UNITED STATES;

EID: 39749161389     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9590-z     Document Type: Article

References (18)

1. EBCTG (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352:930-942
2. The Early Breast Cancer Trialists' Collaborative Group E (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114):1451-1467
3. Hortobagyi G (1997) Docetaxel in combined modality therapy for breast cancer. Oncology 11(6):9-10
4. Henderson IC, Berry D, Demetri G et al. (1998) Improved disease free survival and overall survival from the addition of sequential paclitaxel but not from escalation of doxorubicin in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc Am Soc Clin Onco 17:101
5. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16(8):2672-2685
6. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 24(13):2019-2027
7. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL et al (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 21(22):4165-4174
8. Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborne CK, Dowsett M (1999) Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17(10):3058-3063
9. Tham YL, Gomez LF, Mohsin S, Gutierrez MC, Weiss H, Hilsenbeck SG, Elledge RM, Chamness GC, Osborne CK, Allred DC et al (2005) Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat 94(3):279-284
10. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Guiterrez MC, Elledge RM, Mohsin S, Osborne CK, Chamness GC, Allred DC et al (2003) Gene expression profiling predicts therapeutic response to docetaxel (Taxotere(tm)) in breast cancer patients. Lancet 362:280-287
11. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N et al (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22(12):2284-2293
12. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817-2826
13. Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, Baker J, Walker M, Watson D, Hackett J et al (2006) A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8(3):R25
14. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23):3726-3734
15. Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D et al (2005) Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23(29):7265-7277
16. Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC, Esteban JM, Baker JB (2004) Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase- polymerase chain reaction assay. Am J Pathol 164(1):35-42
17. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK et al (2005) Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 23(6):1169-1177
18. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, Brown A, Yothers G, Anderson S, Smith R et al (2002) Real-world performance of HER2 testing-national surgical adjuvant breast and bowel project experience. J Natl Cancer Inst 94(11):852-854